These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 21454947)
1. Occurrence of overactive bladder in patients with benign prostatic hyperplasia in the Czech Republic. Hanuš T; Zámečník L; Doležal T; Karmazínová Z Urol Int; 2011; 86(4):407-13. PubMed ID: 21454947 [TBL] [Abstract][Full Text] [Related]
2. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. Lee JY; Kim HW; Lee SJ; Koh JS; Suh HJ; Chancellor MB BJU Int; 2004 Oct; 94(6):817-20. PubMed ID: 15476515 [TBL] [Abstract][Full Text] [Related]
3. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. Liu HT; Kuo HC Urology; 2008 Jul; 72(1):104-8; discussion 108. PubMed ID: 18400272 [TBL] [Abstract][Full Text] [Related]
4. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. Athanasopoulos A; Chapple C; Fowler C; Gratzke C; Kaplan S; Stief C; Tubaro A Eur Urol; 2011 Jul; 60(1):94-105. PubMed ID: 21497434 [TBL] [Abstract][Full Text] [Related]
5. Diagnosis and treatment of lower urinary tract symptoms suggestive of overactive bladder and bladder outlet obstruction among men in general practice in the UK. Morant SV; Reilly K; Bloomfield GA; Chapple C Int J Clin Pract; 2008 May; 62(5):688-94. PubMed ID: 18355237 [TBL] [Abstract][Full Text] [Related]
6. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Chapple CR; Roehrborn CG Eur Urol; 2006 Apr; 49(4):651-8. PubMed ID: 16530611 [TBL] [Abstract][Full Text] [Related]
7. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. Irwin DE; Kopp ZS; Agatep B; Milsom I; Abrams P BJU Int; 2011 Oct; 108(7):1132-8. PubMed ID: 21231991 [TBL] [Abstract][Full Text] [Related]
8. Association of symptoms with urodynamic findings in men with overactive bladder syndrome. Al-Zahrani AA; Gajewski JB BJU Int; 2012 Dec; 110(11 Pt C):E891-5. PubMed ID: 22928556 [TBL] [Abstract][Full Text] [Related]
9. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659 [TBL] [Abstract][Full Text] [Related]
10. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Yokoyama T; Uematsu K; Watanabe T; Sasaki K; Kumon H; Nagai A; Scand J Urol Nephrol; 2009; 43(4):307-14. PubMed ID: 19396723 [TBL] [Abstract][Full Text] [Related]
11. Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder. Yokoyama T; Kumon H; Nagai A Neurourol Urodyn; 2008; 27(5):417-20. PubMed ID: 17924444 [TBL] [Abstract][Full Text] [Related]
12. [The pathophysiology underlying overactive bladder syndrome possibly due to benign prostatic hyperplasia]. Akino H; Maegawa M; Nagase K; Tanaka I; Nakai M; Ishida Y; Oyama N; Miwa Y; Yokoyama O Hinyokika Kiyo; 2008 Jun; 54(6):449-52. PubMed ID: 18634444 [TBL] [Abstract][Full Text] [Related]
13. Effects of vibegron, a novel β Maruyama I; Yamamoto S; Tsuchioka K; Yamazaki T Eur J Pharmacol; 2020 Jul; 878():173096. PubMed ID: 32259514 [TBL] [Abstract][Full Text] [Related]
14. [Differential diagnosis and therapy examined under the microscope. LUTS (lower urinary tract symptoms) due to OAB (overactive bladder) - a frequent disease picture in the man]. MMW Fortschr Med; 2011 Mar; 153(13):44-5. PubMed ID: 21638816 [No Abstract] [Full Text] [Related]
15. Defining the role of overactive bladder treatments in men with lower urinary tract symptoms. Lemack GE Nat Clin Pract Urol; 2007 Apr; 4(4):174-5. PubMed ID: 17415351 [No Abstract] [Full Text] [Related]
16. Understanding the elements of overactive bladder: questions raised by the EPIC study. Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K; BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602 [TBL] [Abstract][Full Text] [Related]
17. [Pathophysiology and treatment of the overactive bladder syndrome in an aged male patient with voiding difficulty: pharmacological treatment]. Akino H Hinyokika Kiyo; 2005 Sep; 51(9):609-13. PubMed ID: 16229374 [TBL] [Abstract][Full Text] [Related]
18. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418 [TBL] [Abstract][Full Text] [Related]
19. Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis. Witjes WP; Rosier PF; Caris CT; Debruyne FM; de la Rosette JJ Urology; 1997 Feb; 49(2):197-205; discussion 205-6. PubMed ID: 9037281 [TBL] [Abstract][Full Text] [Related]
20. Antimuscarinics and bladder outlet obstruction: From a contraindication to an indication? Athanasopoulos A Neurourol Urodyn; 2010; 29 Suppl 1():S46-50. PubMed ID: 20127792 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]